Advertisement

Pharmacy World & Science

, Volume 32, Issue 6, pp 701–703 | Cite as

Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism

  • Chaker Ben Salem
  • Lynda Ben Salah
  • Colandane Belajouza
  • Kamel Bouraoui
Case Report

Abstract

Case description A 40-year-old man with pemphigus foliaceus developed a jaundice and pruritis three weeks after starting azathioprine 100 mg daily. Laboratory investigations revealed a severe cholestatic hepatitis. Azathioprine-induced hepatitis was suspected. The dosage of thiopurine methyltransferase activity showed a low activity of the enzyme and the genotype of this enzyme found a TPMT*3C heterozygous mutant allele. Azathioprine was withdrawn. The icterus regressed progressively and the hepatic tests normalised slowly. The patient had no further episodes of hepatitis over a follow-up period of 6 months. Conclusion Although, hematotoxicity seems to be associated with homozygous TPMT variants, a possible association between azathioprine hepatotoxicity and a TPMT*3C genotype should be investigated further.

Keywords

Adverse drug reaction Azathioprine AZT Cholestatic hepatitis Pharmacogenetics  TPMT variants 

Notes

Conflicts of interest

There are no conflicts of interest.

References

  1. 1.
    Fernando SL, Broadfoot AJ. Treatment options for pemphigus foliaceus. G Ital Dermatol Venereol. 2009;144:363–77.PubMedGoogle Scholar
  2. 2.
    Higgs JE, Ayne PK, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11:177–88.CrossRefPubMedGoogle Scholar
  3. 3.
    Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut. 1991;32:715–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol. 1998;12(7):479–83.PubMedGoogle Scholar
  5. 5.
    Du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. Br Med J. 1974;1:49–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R. Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol Clin Biol. 2004;28:720–59.CrossRefPubMedGoogle Scholar
  7. 7.
    Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55:560–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8:367–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9:37–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Xin HW, Xiong H, Wu XC, Li Q, Xiong L, Yu AR. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2009;65:249–55.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Chaker Ben Salem
    • 1
  • Lynda Ben Salah
    • 2
  • Colandane Belajouza
    • 3
  • Kamel Bouraoui
    • 1
  1. 1.Department of Clinical PharmacologyFaculty of Medicine of SousseSousseTunisia
  2. 2.Department of BiophysicsFaculty of Medicine of SousseSousseTunisia
  3. 3.Department of DermatologyFarhat Hached HospitalSousseTunisia

Personalised recommendations